Related Experiment Video
Updated: Jun 7, 2025

Flow Cytometry Analysis of Immune Cells Within Murine Aortas
Published on: July 1, 2011
Novel insights of disulfidptosis-mediated immune microenvironment regulation in atherosclerosis based on
Huanyi Zhao1, Zheng Jin1, Junlong Li1
1First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510405, Guangdong, China.
Abstract:
Atherosclerosis (AS) is the leading cause of coronary heart disease, which is the primary cause of death worldwide. Recent studies have identified disulfidptosis as a new type of cell death that may be involved in onset and development of many diseases. However, the role of disulfidptosis in AS is not clear. In this study, bioinformatics analysis and experiments in vivo and in vitro were performed to evaluate the potential relationship between disulfidptosis and AS. AS-related sequencing data were obtained from the Gene Expression Omnibus (GEO). Bioinformatics techniques were used to evaluate differentially expressed genes (DEGs) associated with disulfidptosis-related AS. Hub genes were screened using least absolute shrinkage and selection operator (LASSO) and random forests (RF) methods. In addition, we established a foam cell model in vitro and an AS mouse model in vivo to verify the expressions of hub genes. In addition, we constructed a diagnostic nomogram with hub genes to predict progression of AS. Finally, the consensus clustering method was used to establish two different subtypes, and associations between subtypes and immunity were explored. As the results, 9 disulfidptosis-related AS DEGs were identified from GSE28829 and GSE43292 datasets. Evaluation of DEGs using LASSO and RF methods resulted in identification of 4 hub genes (CAPZB, DSTN, MYL6, PDLIM1), which were analyzed for diagnostic value using ROC curve analysis and verified in vitro and in vivo. Furthermore, a nomogram including hub genes was established that accurately predicted the occurrence of AS. The consensus clustering algorithm was used to separate patients with early atherosclerotic plaques and patients with advanced atherosclerotic plaques into two disulfidptosis subtypes. Cluster B displayed higher levels of infiltrating immune cells, which indicated that patients in cluster B may have a positive immune response for progression of AS. In summary, disulfidptosis-related genes including CAPZB, DSTN, MYL6, and PDLIM1 may be diagnostic markers and therapeutic targets for AS. In addition, these genes are closely related to immune cells, which may inform immunotherapy for AS.
Insights
Disulfidptosis, a novel cell death, is linked to atherosclerosis (AS). Four genes (CAPZB, DSTN, MYL6, PDLIM1) show diagnostic potential for AS and may guide immunotherapy strategies.
Area of Science:
- Cardiovascular Biology
- Cell Death Mechanisms
- Bioinformatics
Background:
- Atherosclerosis (AS) is a major cause of global mortality.
- Disulfidptosis is an emerging cell death pathway with unclear roles in AS.
- Understanding disulfidptosis in AS is crucial for developing new treatments.
Purpose of the Study:
- To investigate the role of disulfidptosis in atherosclerosis.
- To identify disulfidptosis-related genes as potential diagnostic markers for AS.
- To explore the relationship between disulfidptosis subtypes and immune responses in AS.
Main Methods:
- Bioinformatic analysis of AS datasets (GSE28829, GSE43292).
- Identification of differentially expressed genes (DEGs) and hub genes using LASSO and Random Forests.
- In vitro (foam cell model) and in vivo (AS mouse model) validation of hub genes.
- Construction of a diagnostic nomogram and consensus clustering for AS subtypes.
Main Results:
- Identified 9 disulfidptosis-related DEGs in AS.
- Pinpointed 4 hub genes (CAPZB, DSTN, MYL6, PDLIM1) with diagnostic value for AS.
- Validated hub gene expression in vitro and in vivo.
- Developed a nomogram for accurate AS prediction.
- Defined two disulfidptosis subtypes, with one showing increased immune cell infiltration.
Conclusions:
- Disulfidptosis-related genes (CAPZB, DSTN, MYL6, PDLIM1) are potential diagnostic markers and therapeutic targets for AS.
- These genes are linked to immune cells, suggesting a role in AS immunopathogenesis.
- Findings may inform novel immunotherapy strategies for atherosclerosis.

